These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 56818)

  • 41. Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension.
    Fujisaki K; Kanai H; Hirakata H; Nakamura S; Koga Y; Hattori F; Iida M
    Ther Apher Dial; 2007 Feb; 11(1):49-55. PubMed ID: 17309575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Midodrine efficacy in orthostatic hypotension.
    Singer W; Joyner MJ; Sandroni P; Benarroch EE; Fealey RD; Mandrekar J; Low PA
    J Gen Intern Med; 2014 Nov; 29(11):1440-1. PubMed ID: 25200062
    [No Abstract]   [Full Text] [Related]  

  • 43. Midodrine efficacy in orthostatic hypotension.
    Murad MH; Singh B; Parsaik AA
    J Gen Intern Med; 2014 Nov; 29(11):1442-3. PubMed ID: 25200061
    [No Abstract]   [Full Text] [Related]  

  • 44. [Conservative therapy of female stress incontinence. Double-blind study with the alpha-sympathomimetic midodrin].
    Gnad H; Burmucic R; Petritsch P; Steindorfer P
    Fortschr Med; 1984 May; 102(20):578-80. PubMed ID: 6203818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of midodrine on experimentally induced postural hypotension and venous pooling in dogs.
    Yamazaki R; Tsuchida K; Aihara H
    Res Commun Chem Pathol Pharmacol; 1987 Dec; 58(3):323-37. PubMed ID: 2449710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059.
    Pittner H; Stormann H; Enzenhofer R
    Arzneimittelforschung; 1976; 26(12):2145-54. PubMed ID: 66056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Midodrine (Gutron) treatment of permanent arterial hypotension in a chronic hemodialysis patient].
    Montagnac R; Clavel P; Delhotal-Landes B; Flouvat B; Poulain S; Schillinger F
    Nephrologie; 2000; 21(4):179-83. PubMed ID: 10976433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study.
    Kaufmann H; Saadia D; Voustianiouk A
    Ann Neurol; 2002 Sep; 52(3):342-5. PubMed ID: 12205647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Update on the evaluation, pathogenesis, and management of neurogenic orthostatic hypotension: introduction.
    Low PA
    Neurology; 1995 Apr; 45(4 Suppl 5):S4-5. PubMed ID: 11536688
    [No Abstract]   [Full Text] [Related]  

  • 50. [Investigations of the effect of midodrine on carbohydrate and fat metabolism with particular reference to the diabetic metabolic state (author's transl)].
    Brändle J; Lageder H; Irsigler K
    Wien Klin Wochenschr; 1977 Mar; 89(5):164-7. PubMed ID: 65840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
    Cruz DN; Mahnensmith RL; Brickel HM; Perazella MA
    Clin Nephrol; 1998 Aug; 50(2):101-7. PubMed ID: 9725781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of retrograde ejaculation and anorgasm with an alpha-sympathomimetic agent (Midodrin)].
    Schwale M; Frosch P; Tölle E; Niermann H
    Z Hautkr; 1980 Jun; 55(11):756-9. PubMed ID: 6158188
    [No Abstract]   [Full Text] [Related]  

  • 53. [Treatment of orthostatic hypotension due to major hypotensive drugs (exception of ganglioplegics). Trial of dihydroergotamine].
    Conte J; Ader JL; Suc JM
    Nouv Presse Med; 1973 Jun; 2(26):1761-4. PubMed ID: 4724042
    [No Abstract]   [Full Text] [Related]  

  • 54. Use of midodrine (Gutron) to treat permanent hypotension in a chronic hemodialysis patient.
    Montagnac R; Clavel P; Delhotal-Landes B; Flouvat B; Poulain S; Schllinger F
    Clin Nephrol; 2001 Aug; 56(2):162-8. PubMed ID: 11522094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapy of orthostatic dysregulation. Comparative studies on anti-hypotensive sympathomimetics with a tilt-table test].
    Lossnitzer K; Gäb J
    Fortschr Med; 1980 Aug; 98(29):(1133-6). PubMed ID: 6108908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trials to address efficacy of midodrine 18 years after it gains FDA approval.
    Mitka M
    JAMA; 2012 Mar; 307(11):1124, 1127. PubMed ID: 22436941
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment of retrograde ejaculationin paraplegia.
    Schütte B; Medenwaldt B
    Andrologia; 1980; 12(4):389-90. PubMed ID: 6158892
    [No Abstract]   [Full Text] [Related]  

  • 58. [Dihydroergotamine in orthostatic dysregulation].
    Heck J
    Med Klin; 1971 Apr; 66(16):601-4. PubMed ID: 5552926
    [No Abstract]   [Full Text] [Related]  

  • 59. [The pharmacological properties of Midodrin and its clinical application in patients with hypotensive circulatory disturbance (author's transl)].
    Lachner O; Lillie C; Rot A
    Wien Klin Wochenschr; 1974 Jun; 86(12):344-8. PubMed ID: 4600383
    [No Abstract]   [Full Text] [Related]  

  • 60. [Treatment of hypotensive circulatory dysregulation with a combination of dihydroergotamine and etilefrine (author's transl)].
    Bracharz H; Polzien P
    MMW Munch Med Wochenschr; 1981 Jan; 123(5):177-80. PubMed ID: 6110188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.